{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,10]],"date-time":"2026-08-10T21:35:18Z","timestamp":1786397718990,"version":"build-2736575974"},"reference-count":19,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2024,5,13]],"date-time":"2024-05-13T00:00:00Z","timestamp":1715558400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2024,5,13]],"date-time":"2024-05-13T00:00:00Z","timestamp":1715558400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100003286","name":"Kuwait Foundation for the Advancement of Sciences","doi-asserted-by":"crossref","award":["PR1713MM03"],"award-info":[{"award-number":["PR1713MM03"]}],"id":[{"id":"10.13039\/501100003286","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Cancer"],"abstract":"<jats:title>Abstract<\/jats:title><jats:p>In chronic lymphocytic leukaemia (CLL), comorbidities assessed by the CLL comorbidity index (CLL-CI) have been associated with outcomes in Western cohorts. We conducted a retrospective analysis of an unselected Middle Eastern cohort of newly diagnosed CLL patients seen at the Kuwait Cancer Control Center (<jats:italic>n<\/jats:italic>\u2009=\u2009300). Compared to Western studies, these Middle Eastern patients were diagnosed at a younger age (median of 59) and had a higher comorbidity burden (69% non-low risk CLL-CI). A higher CLL-CI score was independently associated with significantly shorter event-free survival and greater risk of death. Our analysis demonstrates that CLL-CI is a valuable tool for comorbidity assessment and prognostic influence in (relatively young) Middle Eastern CLL patients.<\/jats:p>","DOI":"10.1186\/s12885-024-12343-1","type":"journal-article","created":{"date-parts":[[2024,5,13]],"date-time":"2024-05-13T06:02:50Z","timestamp":1715580170000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":8,"title":["Prognostic impact of chronic lymphocytic leukemia comorbidity index in a young population: a real-world evidence study of a national gulf region cohort"],"prefix":"10.1186","volume":"24","author":[{"given":"Salem H.","family":"Alshemmari","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ahmad","family":"AlSarraf","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andy","family":"Kaempf","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alexey V.","family":"Danilov","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2024,5,13]]},"reference":[{"key":"12343_CR1","doi-asserted-by":"crossref","DOI":"10.1007\/978-1-4939-8876-1","volume-title":"Chronic lymphocytic leukemia","author":"M Hallek","year":"2019","unstructured":"Hallek M, Eichhorst B, Catovsky D. Chronic lymphocytic leukemia. Cham: Springer International Publishing; 2019."},{"key":"12343_CR2","doi-asserted-by":"publisher","first-page":"49","DOI":"10.1182\/blood-2014-02-556399","volume":"124","author":"N Pflug","year":"2014","unstructured":"Pflug N, Bahlo J, Shanafelt TD, et al. Development of a comprehensive prognostic index for patients with chronic lymphocytic leukemia. Blood. 2014;124:49\u201362. https:\/\/doi.org\/10.1182\/blood-2014-02-556399.","journal-title":"Blood"},{"key":"12343_CR3","doi-asserted-by":"publisher","first-page":"E176","DOI":"10.1002\/ajh.26502","volume":"97","author":"S Molica","year":"2022","unstructured":"Molica S, Giannarelli D, Visentin A, et al. Prediction of outcomes in chronic lymphocytic leukemia patients treated with ibrutinib: validation of current prognostic models and development of a simplified three-factor model. Am J Hematol. 2022;97:E176\u201380. https:\/\/doi.org\/10.1002\/ajh.26502.","journal-title":"Am J Hematol"},{"key":"12343_CR4","doi-asserted-by":"publisher","first-page":"49","DOI":"10.1080\/10428190701724785","volume":"49","author":"P Thurmes","year":"2008","unstructured":"Thurmes P, Call T, Slager S, et al. Comorbid conditions and survival in unselected, newly diagnosed patients with chronic lymphocytic leukemia. Leuk Lymphoma. 2008;49:49\u201356. https:\/\/doi.org\/10.1080\/10428190701724785.","journal-title":"Leuk Lymphoma"},{"key":"12343_CR5","doi-asserted-by":"publisher","first-page":"779","DOI":"10.1016\/S1470-2045(16)30029-8","volume":"17","author":"International CLL-IPI working group","year":"2016","unstructured":"International CLL-IPI working group. An international prognostic index for patients with chronic lymphocytic leukaemia (CLL-IPI): a meta-analysis of individual patient data. Lancet Oncol. 2016;17:779\u201390. https:\/\/doi.org\/10.1016\/S1470-2045(16)30029-8.","journal-title":"Lancet Oncol"},{"key":"12343_CR6","doi-asserted-by":"publisher","first-page":"5490","DOI":"10.1182\/bloodadvances.2021004824","volume":"5","author":"A Tedeschi","year":"2021","unstructured":"Tedeschi A, Frustaci AM, Mauro FR, et al. Do age, fitness, and concomitant medications influence management and outcomes of patients with CLL treated with ibrutinib? Blood Adv. 2021;5:5490\u2013500. https:\/\/doi.org\/10.1182\/bloodadvances.2021004824.","journal-title":"Blood Adv"},{"key":"12343_CR7","doi-asserted-by":"publisher","first-page":"928","DOI":"10.1016\/S1470-2045(16)30051-1","volume":"17","author":"B Eichhorst","year":"2016","unstructured":"Eichhorst B, Fink A-M, Bahlo J, et al. First-line chemoimmunotherapy with bendamustine and rituximab versus fludarabine, cyclophosphamide, and Rituximab in patients with advanced chronic lymphocytic leukaemia (CLL10): an international, open-label, randomised, phase 3, non-inferiority trial. Lancet Oncol. 2016;17:928\u201342. https:\/\/doi.org\/10.1016\/S1470-2045(16)30051-1.","journal-title":"Lancet Oncol"},{"key":"12343_CR8","doi-asserted-by":"publisher","first-page":"4814","DOI":"10.1158\/1078-0432.CCR-20-3993","volume":"27","author":"MJ Gordon","year":"2021","unstructured":"Gordon MJ, Kaempf A, Sitlinger A, et al. The chronic lymphocytic leukemia comorbidity index (CLL-CI): a three-factor comorbidity model. Clin Cancer Res. 2021;27:4814\u201324. https:\/\/doi.org\/10.1158\/1078-0432.CCR-20-3993.","journal-title":"Clin Cancer Res"},{"key":"12343_CR9","doi-asserted-by":"publisher","first-page":"2701","DOI":"10.1182\/bloodadvances.2021005716","volume":"6","author":"EC Rotbain","year":"2022","unstructured":"Rotbain EC, Gordon MJ, Vainer N, et al. The CLL comorbidity index in a population-based cohort: a tool for clinical care and research. Blood Adv. 2022;6:2701\u20136. https:\/\/doi.org\/10.1182\/bloodadvances.2021005716.","journal-title":"Blood Adv"},{"key":"12343_CR10","doi-asserted-by":"publisher","first-page":"106668","DOI":"10.1016\/j.leukres.2021.106668","volume":"110","author":"SH Alshemmari","year":"2021","unstructured":"Alshemmari SH, Hamdah A, Pandita R, Kunhikrishnan A. Chronic lymphocytic leukemia in a young population. Leuk Res. 2021;110:106668. https:\/\/doi.org\/10.1016\/j.leukres.2021.106668.","journal-title":"Leuk Res"},{"key":"12343_CR11","doi-asserted-by":"publisher","first-page":"105","DOI":"10.2217\/ijh-2017-0019","volume":"6","author":"EE Rassy","year":"2017","unstructured":"Rassy EE, Chebly A, Korban R, et al. Untreated chronic lymphocytic leukemia in Lebanese patients: an observational study using standard karyotyping and FISH. Int J Hematol Oncol. 2017;6:105\u201311. https:\/\/doi.org\/10.2217\/ijh-2017-0019.","journal-title":"Int J Hematol Oncol"},{"key":"12343_CR12","doi-asserted-by":"publisher","first-page":"394","DOI":"10.1111\/bjh.14785","volume":"178","author":"P Strati","year":"2017","unstructured":"Strati P, Parikh SA, Chaffee KG, et al. Relationship between co-morbidities at diagnosis, survival and ultimate cause of death in patients with chronic lymphocytic leukaemia (CLL): a prospective cohort study. Br J Haematol. 2017;178:394\u2013402. https:\/\/doi.org\/10.1111\/bjh.14785.","journal-title":"Br J Haematol"},{"key":"12343_CR13","first-page":"79","volume":"8","author":"S ALNohair","year":"2014","unstructured":"ALNohair S. Obesity in Gulf Countries. Int J Health Sci (Qassim). 2014;8:79\u201383.","journal-title":"Int J Health Sci (Qassim)"},{"key":"12343_CR14","first-page":"1303","volume":"21","author":"SA Meo","year":"2017","unstructured":"Meo SA, Usmani AM, Qalbani E. Prevalence of type 2 diabetes in the arab world: impact of GDP and energy consumption. Eur Rev Med Pharmacol Sci. 2017;21:1303\u201312.","journal-title":"Eur Rev Med Pharmacol Sci"},{"key":"12343_CR15","doi-asserted-by":"publisher","first-page":"350","DOI":"10.1038\/s41574-021-00487-0","volume":"17","author":"KA Brown","year":"2021","unstructured":"Brown KA. Metabolic pathways in obesity-related breast cancer. Nat Rev Endocrinol. 2021;17:350\u201363. https:\/\/doi.org\/10.1038\/s41574-021-00487-0.","journal-title":"Nat Rev Endocrinol"},{"key":"12343_CR16","doi-asserted-by":"publisher","first-page":"2706","DOI":"10.3748\/wjg.v25.i22.2706","volume":"25","author":"G Bruno","year":"2019","unstructured":"Bruno G, Zaccari P, Rocco G, et al. Proton pump inhibitors and dysbiosis: current knowledge and aspects to be clarified. WJG. 2019;25:2706\u201319. https:\/\/doi.org\/10.3748\/wjg.v25.i22.2706.","journal-title":"WJG"},{"key":"12343_CR17","doi-asserted-by":"publisher","first-page":"2238","DOI":"10.3324\/haematol.2021.280455","volume":"107","author":"T Faitov\u00e1","year":"2022","unstructured":"Faitov\u00e1 T, Svanberg R, Da Cunha-Bang C, et al. The gut microbiome in patients with chronic lymphocytic leukemia. Haematol. 2022;107:2238\u201343. https:\/\/doi.org\/10.3324\/Haematol.2021.280455.","journal-title":"Haematol"},{"key":"12343_CR18","doi-asserted-by":"publisher","unstructured":"Zitvogel L, Galluzzi L, Viaud S, et al. Cancer and the gut microbiota: an unexpected link. Sci Transl Med. 2015;7. https:\/\/doi.org\/10.1126\/scitranslmed.3010473.","DOI":"10.1126\/scitranslmed.3010473"},{"key":"12343_CR19","doi-asserted-by":"publisher","first-page":"E306","DOI":"10.1002\/ajh.26235","volume":"96","author":"F Morabito","year":"2021","unstructured":"Morabito F, Del Poeta G, Mauro FR, et al. TP53 disruption as a risk factor in the era of targeted therapies: a multicenter retrospective study of 525 chronic lymphocytic leukemia cases. Am J Hematol. 2021;96:E306\u201310. https:\/\/doi.org\/10.1002\/ajh.26235.","journal-title":"Am J Hematol"}],"container-title":["BMC Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12885-024-12343-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12885-024-12343-1\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12885-024-12343-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,5,13]],"date-time":"2024-05-13T06:03:19Z","timestamp":1715580199000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmccancer.biomedcentral.com\/articles\/10.1186\/s12885-024-12343-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,5,13]]},"references-count":19,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2024,12]]}},"alternative-id":["12343"],"URL":"https:\/\/doi.org\/10.1186\/s12885-024-12343-1","relation":{},"ISSN":["1471-2407"],"issn-type":[{"value":"1471-2407","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,5,13]]},"assertion":[{"value":"28 January 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"6 May 2024","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"13 May 2024","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"A statement to confirm that all experimental protocols were approved by the Ministry of Health institutional review board. Informed consent was obtained from all subjects.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"584"}}